Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Alpha L-Iduronidase market pipeline research report provides comprehensive information on the Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics development with respective active and dormant or discontinued projects.

Key MoA in the Alpha L-Iduronidase Pipeline Market

The key MoA in the Alpha L-Iduronidase pipeline market are Alpha L-Iduronidase Activator and Alpha L-Iduronidase Replacement. Alpha L-Iduronidase Activator has the highest number of pipeline products.

Alpha L-Iduronidase Pipeline Market, by MoA

Alpha L-Iduronidase Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Alpha L-Iduronidase Pipeline Market

The key RoA in the Alpha L-Iduronidase pipeline market are intravenous, intracisternal, intracerebral, oral, and parenteral. Intravenous has the highest number of pipeline products.

Alpha L-Iduronidase Pipeline Market, by RoA

Alpha L-Iduronidase Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Alpha L-Iduronidase Pipeline Market

The key molecule types in the Alpha L-Iduronidase pipeline market are gene therapy, gene-modified cell therapy, fusion protein, recombinant enzyme, small molecule, oligonucleotide, and recombinant protein.

Alpha L-Iduronidase Pipeline Market, by Molecule Types

Alpha L-Iduronidase Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Alpha L-Iduronidase Pipeline Market

The key companies in the Alpha L-Iduronidase pipeline market are RegenxBio Inc, ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc, Ossianix Inc, RainBio Inc, and RegenxBio Inc.

Alpha L-Iduronidase Pipeline Market, by Companies

Alpha L-Iduronidase Pipeline Market, by Companies

For more molecule type insights, download a free report sample

Market report overview

Key MoA Alpha L-Iduronidase Activator and Alpha L-Iduronidase Replacement
Key RoA Intravenous, Intracisternal, Intracerebral, Oral, and Parenteral
Key molecule types Gene Therapy, Gene-Modified Cell Therapy, Fusion Protein, Recombinant Enzyme, Small Molecule, Oligonucleotide, and Recombinant Protein
Key companies RegenxBio Inc, ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc, Ossianix Inc, RainBio Inc, and RegenxBio Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
  • The report reviews Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alpha L-Iduronidase (IDUA or EC 3.2.1.76) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

ArmaGen Inc
BioStrategies LC
Denali Therapeutics Inc
EdiGene Inc
Gain Therapeutics Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
Orchard Therapeutics Plc
Ossianix Inc
RainBio Inc
RegenxBio Inc
Sigilon Therapeutics Inc
Tega Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alpha L-Iduronidase (IDUA or EC

3.2.1.76) – Overview

Alpha L-Iduronidase (IDUA or EC

3.2.1.76) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha L-Iduronidase (IDUA or EC

3.2.1.76) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha L-Iduronidase (IDUA or EC

3.2.1.76) – Companies Involved in Therapeutics Development

ArmaGen Inc

BioStrategies LC

Denali Therapeutics Inc

EdiGene Inc

Gain Therapeutics Inc

Immusoft Corp

JCR Pharmaceuticals Co Ltd

Orchard Therapeutics Plc

Ossianix Inc

RainBio Inc

RegenxBio Inc

Sigilon Therapeutics Inc

Tega Therapeutics Inc

Alpha L-Iduronidase (IDUA or EC

3.2.1.76) – Drug Profiles

AGT-181 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I – Drug Profile

Product Description

Mechanism Of Action

History of Events

Fusion Protein to Replace IDUA for Mucopolysaccharidosis I – Drug Profile

Product Description

Mechanism Of Action

ISP-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

laronidase – Drug Profile

Product Description

Mechanism Of Action

History of Events

Oligonucleotide to Activate IDUA for Hurler Syndrome, Unspecified Cancer, Unspecified Muscular Diseases, Unspecified Neurologic Disorders, and Unspecified Non-Genetic Diseases – Drug Profile

Product Description

Mechanism Of Action

History of Events

OTL-203 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RBIO-1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Alpha L-Iduronidase Replacement for Mucopolysaccharidosis I (MPS I) – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I – Drug Profile

Product Description

Mechanism Of Action

History of Events

RGX-111 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SIG-005 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TXB-4LS1 – Drug Profile

Product Description

Mechanism Of Action

X-372 – Drug Profile

Product Description

Mechanism Of Action

Alpha L-Iduronidase (IDUA or EC

3.2.1.76) – Dormant Products

Alpha L-Iduronidase (IDUA or EC

3.2.1.76) – Product Development Milestones

Featured News & Press Releases

Feb 09, 2022: REGENXBIO presents positive initial data from Phase I/II of RGX-111 for the treatment of severe MPS I at 18th annual WORLDSymposium 2022

Feb 07, 2022: Immusoft to present at WORLDSymposium 2022 Conference

Feb 04, 2022: JCR pharmaceuticals to present posters on JR-171 at the 18th annual WORLDSymposium 2022

Jan 31, 2022: Sigilon Therapeutics to present preclinical data at the 18th Annual WORLDSymposium on Lysosomal Diseases, MPS-1 and MPS-6

Nov 18, 2021: Orchard Therapeutics announces new New England Journal Medicine publication of interim proof-of-concept study results of OTL-203 for Hurler Syndrome

Oct 05, 2021: JCR Pharmaceuticals: US FDA grants Fast Track Designation for JR-171 for the treatment of Mucopolysaccaridosis Type I (MPSI)

Sep 09, 2021: Sigilon Therapeutics announces acceptance of clinical trial application in the UK for SIG-005 for the treatment of mucopolysaccharidosis type I

Jul 23, 2021: Sigilon Therapeutics presents preclinical data at the 16th International Symposium on MPS and Related Diseases

Mar 30, 2021: EMA grants Orphan Drug Designation to JR-171 for the treatment of Mucopolysaccaridosis Type I (MPS I)

Feb 12, 2021: US FDA grants orphan drug designation to JR-171 for the treatment of Mucopolysaccaridosis Type I (MPS I)

Feb 09, 2021: Orchard Therapeutics announces interim data for OTL-203 showing positive clinical results in multiple disease manifestations of mucopolysaccharidosis type I Hurler syndrome (MPS-IH)

Jan 28, 2021: Orchard Therapeutics to present abstact on OTL-203 at 2021 WORLDSymposium

Dec 17, 2020: Sigilon Therapeutics receives Orphan Drug Designation for SIG-005 for the treatment of mucopolysaccharidosis type I

Dec 01, 2020: RegenxBio announces dosing of first patient in phase I/II trial of RGX-111 for the treatment of Mucopolysaccharidosis type I

Oct 30, 2020: JCR announces first patient dosed in phase 1/2 global clinical trial of JR-171 for mucopolysaccharidosis type I (MPS I)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by ArmaGen Inc, 2022

Pipeline by BioStrategies LC, 2022

Pipeline by Denali Therapeutics Inc, 2022

Pipeline by EdiGene Inc, 2022

Pipeline by Gain Therapeutics Inc, 2022

Pipeline by Immusoft Corp, 2022

Pipeline by JCR Pharmaceuticals Co Ltd, 2022

Pipeline by Orchard Therapeutics Plc, 2022

Pipeline by Ossianix Inc, 2022

Pipeline by RainBio Inc, 2022

Pipeline by RegenxBio Inc, 2022

Pipeline by Sigilon Therapeutics Inc, 2022

Pipeline by Tega Therapeutics Inc, 2022

Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.